Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
N/A
-282 Reduced 2.69%
10,219 $33,000
Q4 2023

Feb 14, 2024

BUY
N/A
262 Added 2.56%
10,501 $34,000
Q3 2023

Nov 13, 2023

BUY
N/A
10,239 New
10,239 $33,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.